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The  Mexican  Government  developed  a  plan  in  2004  for pandemic  inﬂuenza  preparedness  that  included
local  production  of  inﬂuenza  vaccine.  To  achieve  this,  an agreement  was  concluded  between  Birmex  –
a  state-owned  vaccine  manufacturer  –  and  sanoﬁ  pasteur,  a  leading  developer  of vaccine  technology.
Under  this  agreement,  sanoﬁ  pasteur  will  establish  a facility  in  Mexico  to  produce  antigen  for  up  to  30
million  doses  of  egg-based  seasonal  vaccine  per year, and  Birmex  will  build  a  facility  to  formulate,  ﬁll  and
package  the inactivated  split-virion  inﬂuenza  vaccine.  As at November  2010,  the sanoﬁ  pasteur  facility
has  been  completed  and  the  Birmex  plant  is  under  construction.  Most  of  the  critical  equipment  has  been
purchased  and  is in  the  process  of  validation.  In  addition  to intensive  support  from  sanoﬁ  pasteur  for  the
transfer  of the  technology,  the  project  is  supported  by the  Mexican  Ministry  of  Health,  complemented
by  Birmex’s  own  budget  and  grants  from  the WHO  developing  country  inﬂuenza  technology  transfer
project.. Introduction
In Mexico, about 14 000 people die each year from acute respi-
atory infections, including inﬂuenza which affects mostly children
nder 3 and adults over 60 years of age. The recent A(H1N1)
nﬂuenza pandemic had a severe impact in our country: more than
2 000 cases were diagnosed, of which 1316 died [1]. Preliminary
esults of a small serum survey carried out by the Ministry of Health
ndicate that at least 30% of the population was  infected during
009–2010. Although, luckily, the case—fatality rate was  relatively
ow, the health system suffered enormously and emergency ser-
ices and intensive care units were overcrowded [2,3].
In  1999, the World Health Organization (WHO) disseminated an
nﬂuenza Pandemic Plan with guidelines to assist medical and pub-
ic health leaders to be able to respond to the threat of an inﬂuenza
andemic [4]. The recent H1N1 pandemic reinforces the need to
eed the recommendations in the guidelines, which outline the
omplementary roles and responsibilities of WHO  and national
uthorities at the onset of an inﬂuenza pandemic. For example,
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WHO  strongly recommends that all countries establish multi-
disciplinary National Pandemic Planning Committees to develop
strategies appropriate for their countries in advance of the next
pandemic.
Because of the higher morbidity and mortality associated with
seasonal inﬂuenza in the very young and the elderly, Mexico
included vaccination against inﬂuenza as a priority in 2004 and
offered free vaccination for all children under 3 years and adults
over 60 years of age. Since then, the use of inﬂuenza vaccine in our
country has increased gradually to reach nearly 23 million doses in
2010 (Fig. 1).
2.  Mexico’s strategy for inﬂuenza pandemic vaccination
In  2007, the Mexican General Board of Health decreed the
establishment of a multisectoral Operational Strategy within the
National Preparedness and Response to Pandemic Inﬂuenza Plan,
and instructed Birmex, a state-owned company, to take immediate
action to develop domestic production of seasonal and – if needed
– pandemic vaccine against inﬂuenza.
At that time, Birmex considered three different alternatives. The
ﬁrst was  to develop in-house technology to develop and market
Open access under CC BY-NC-ND license.inﬂuenza vaccine. However, the lengthy time frame to license a
vaccine, including preclinical and clinical trials, raised concerns
that a pandemic could occur before a vaccine became available.
Since the primary objective of the Government was  to protect the
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ig. 1. Number of doses of seasonal inﬂuenza vaccine used in Mexico, 2005–2010.
opulation, the success of this option could not be guaranteed. A
econd alternative was to acquire the technology. Even though this
ay  have combined the beneﬁts of owning the technology and
educing the delay to the launch of a vaccine, we  were unable to
dentify a willing technology provider.
The third, adopted alternative was to establish a joint venture
ith an internationally recognized vaccine company that would be
ommitted to establish the whole production process in Mexico.
nder a technology transfer agreement signed in 2008, sanoﬁ pas-
eur became our technology partner. For its part, sanoﬁ pasteur
greed to build a facility in Ocoyoacac to produce the antigen and,
ending completion of the facility, assure the supply of 30 million
oses of seasonal vaccine per year. In addition, should an inﬂuenza
andemic occur before vaccine production in Mexico became oper-
tional, sanoﬁ pasteur would make pandemic vaccine available to
he Government of Mexico. The responsibility of Birmex was  to
uild a Good Manufacturing Practice (GMP)-compliant facility to
ormulate, ﬁll and package (FFP) the seasonal – and eventually pan-
emic – inﬂuenza  vaccine. To this end, a site in Cuautitlan was
cquired.
When WHO  started its initiative in 2007 to support devel-
ping country vaccine manufacturers to increase the world’s
nﬂuenza vaccine production capacity, Birmex was successful in
ecoming one of the six initial grantees. Our proposal to WHO
o support the construction of the FFP facility was  consistent
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with  the joint venture with our technology partner. The project
comprised the transfer of technology from our partner to ﬁll-
ﬁnish and package egg-based split virion inactivated inﬂuenza
vaccine (seasonal and pandemic) to cover initially the domestic
market. This included plant design, engineering production, qual-
ity control (QC), qualiﬁcation, validation and regulatory affairs.
Milestones of the complete inﬂuenza project are outlined in
Fig. 2.
The facility will have a capacity for 30 million doses of triva-
lent seasonal vaccine per year in 10-dose vials, with potential
to increase capacity to 60 million doses of southern hemisphere
formulation. If needed, capacity could be converted to produce
approximately 60 million doses of pandemic vaccine, and consid-
eration may  be given to extending production beyond Mexican
demand.
The development plan includes all issues related to the pro-
duction process – organization planning, engineering layout,
remodelling work, documentation, training, procurement of equip-
ment, commissioning, qualiﬁcation and validation – following
international and national regulatory requirements.
3. Remodelling the blending, ﬁlling and packaging facility
Once  the technology transfer agreement with sanoﬁ pasteur was
signed, a recognized pharmaceutical engineering ﬁrm was  hired
to elaborate the master plan for the Cuautitlan facility, based on
Birmex’s strategic plan. The consulting ﬁrm developed a detailed
engineering plan for the FFP and Quality Control facility, including
the structural civil engineering, architectonic and masonry layouts,
speciﬁcations of all necessary systems, equipment and materi-
als. In 2009, the ofﬁce area was completed and 160 of Birmex’s
700 employees moved in. In addition, the store house became
functional for company-wide activities. In parallel to this activity,
Birmex recruited an international expert team to ensure compli-
ance of the facility with GMP, including regulatory review of the
designs and development of the qualiﬁcation protocols. This part
of the project is on track to be completed in mid  2013 with full
production planned to start in September 2014, when antigen pro-
duced in the sanoﬁ-built plant will be blended, ﬁlled and packaged
in Cuautitlan.
oject, Mexico, 2010–2014.
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.1. Equipment
Birmex has acquired much of the critical production and QC lab-
ratory equipment with the same speciﬁcations as those of sanoﬁ
asteur at its site in France. Both Birmex and sanoﬁ technicians
ere involved in the factory acceptance tests for design speciﬁ-
ations, alarm systems and functionality of the equipment. Some
ritical QC laboratory equipment, such as the isolator, autoclaves
nd washing machines had already passed factory acceptance tests.
dditional QC equipment was procured with resources from WHO.
.2. Training
An  essential element for the successful development of the
roject was the training of personnel. In April 2008, Birmex techni-
ians joined other grantees at the WHO-facilitated training course
eld at the National Institute for Biological Standards and Con-
rol (NIBSC). During this training in QC tests for inﬂuenza vaccine,
e acquired competence in performing tests to evaluate Single
adial Diffusion (SRID) potency, Limulus Amebocyte Lysate (LAL),
ndotoxin and Polyacrilamide Agarose Gel Electrophoresis (PAGE)
urity.
The transfer of critical analytical methods, in line with the tech-
ology transfer guidelines [5] entailed training of the lead QC team
rom Birmex in physicochemical and microbiological methods at
anoﬁ pasteur’s laboratories in France. Workshops for produc-
ion, manufacturing technology and engineering were also held in
rance. In parallel, all documentation required for the technology
ransfer, such as training modules and standard operating proce-
ures, is being developed.
.  Financial resources and fund administration
Resources for the project have come mainly from the Federal
overnment and Birmex. Sanoﬁ pasteur is ﬁnancing directly the
ntigen production facility. The two grants provided by WHO  have
een instrumental, not only for their ﬁnancial support to important
ctivities, but for the tremendous credence they have lent to the
roject: WHO  support has been pivotal when presenting the project
o other stakeholders and very signiﬁcant in the fund-raising pro-
ess.
The ﬁnancial support of the Ministry of Health was  comple-
ented by Birmex retained proﬁts to ensure the completion of the
MP-compliant inﬂuenza facility. Grants received from WHO  rep-
esent almost 3% of the total investment required for the project.
n order to optimize the WHO  inﬂuenza grant, Birmex contracted
 collaborative agreement to administer the funds with the Mexi-
an Health Foundation. This approach has had several beneﬁts such
s easier auditing and a higher level of ﬂexibility in assigning the
esources.
. Discussion
The Birmex-sanoﬁ technology transfer agreement combines the
eneﬁts of a multinational vaccine producer with the social com-
itment and goals of a government-owned company. An example
f this was the ability to fast track the registration of the A(H1N1)
accine in Mexico in 2009, thus providing rapid access to the mono-
alent pandemic vaccine for the Mexican population. This model
ould lead to a larger product portfolio of state-owned manufac-
urers for the beneﬁt of their populations.
[
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Given  the complexity and scope of this kind of project, we  evi-
dently encountered certain difﬁculties unforeseen during the initial
planning stages. These included devoting human resources exclu-
sively to the project, the procurement process and the availability of
adequate ﬁnancial resources. Birmex has been successful in resolv-
ing the majority of these hurdles during the development of the
project to achieve its ultimate objectives.
The expansion of our technology transfer agreement beyond
Mexico, e.g. to explore further South–South arrangements for
the exchange of vaccine formulations, may  support sustainability
but will clearly depend on negotiation with the technology part-
ner.
6. Conclusions
Being a grantee of the WHO  technology transfer initiative has
lent credibility to the Mexican Government Pandemic Inﬂuenza
Preparedness and Response Plan, which includes a seasonal
inﬂuenza immunization programme and the domestic production
of inﬂuenza vaccine. WHO  expert visits have been impressed with
progress made and the excellent collaboration between Birmex
and its technology partner, sanoﬁ pasteur. Mexico is on track to
be able to produce inﬂuenza vaccine for seasonal – and pandemic –
use by 2014. The project is sustainable since routine immunization
against inﬂuenza is already in place and backed up with the pro-
vision of a long-term advanced purchase agreement for inﬂuenza
vaccine.
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